These companies use the creative forces of capitalism to solve big problems—and do well by doing good.

<p>Gilead is a longtime leader in HIV therapeutics and prevention, including antiretroviral treatment and pre-exposure prophylaxis (PrEP) medicines, which are drugs taken to lower the risk of contracting HIV. Gilead has worked with the government of South Africa and the Global Fund to accelerate access to lenacapavir, a long-acting prevention medication that the FDA approved in 2022 to treat drug-resistant HIV. Approximately 7.8 million people in South Africa live with HIV, with an estimated 170,000 new infections each year. 
</p>

Change the World

With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

<p>Gilead’s drugs have helped change HIV infection from a death sentence to a manageable condition. In 2012, it launched the first pre-exposure prophylaxis (PrEP) preventive drug for HIV. In June, it won FDA approval for Yeztugo, a PrEP drug requiring only two doses a year—giving it far greater potential efficacy in preventing new infections.
</p>

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The companies on this list are mobilizing the creative tools of capitalism to help solve social problems.

CTW 2023-Gilead

Although the southern United States represent only 33% of the U.S. population, they account for 51% of new HIV diagnoses and 47% of HIV-related deaths in the country. Gilead, which makes a variety of HIV drugs, has launched the Compass Initiative to tackle the factors fueling that disparity. In partnership with more than 390 community organizations across 16 states, Compass’s events and training programs focus on topics including stigma reduction and trauma-informed medical care, with the aim of helping those community groups do more to help combat the spread of HIV. To date, Compass has provided 300,000 people with services, trained 26,000 individuals in leadership development, and provided more than $106 million in grant funding to support outreach to those impacted by HIV.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

This year’s Fortune 500 marks the 68th running of the list.

Total revenue for the world’s biggest companies fell 4.8% to $31.7 trillion this year—the first decline in half a decade.

The biopharmaceutical company researches and develops antiviral drugs used in the treatment of life-threatening diseases, including HIV and hepatitis. Last October, its intravenous drug remdesivir became the first treatment for COVID-19 approved for emergency use by the FDA.

Fortune Global 500

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-116-Gilead Sciences

This year's Fortune 500 marks the 66th running of the list.

F500-2020-140-Gilead-Sciences

California-based Gilead is a biopharmaceutical firm best known for its hepatitis C cures Sovaldi and Harvoni, though it's been making headlines more recently due to its experimental coronavirus treatment remdesivir.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune Global 500 generated $27.7 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 64th running of the list.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

World's Most Admired Companies

This year's Fortune 500 marks the 63rd running of the list.

Everybody loves an up-and-comer: 2017's top three-year performers in revenues, profits, and stock returns.

100 Fastest-Growing Companies

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.6 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 62nd running of the list.

Here’s our look at 50 companies that do well by doing good.

Too fast to be stopped: 2016's top three-year performers in revenue, profits, and stock returns.

The world's 500 largest companies generated $31.2 trillion in revenues and $1.7 trillion in profits in 2014. Together, this year's Fortune Global 500 employ 65 million people worldwide and are represented by 36 countries.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

This year's Fastest-Growing Companies marks the 19th running of the list. In our annual list of public companies with the most stellar three-year profit, revenue, and stock growth, Facebook makes its first appearance.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Company Info

Industry

Location

Industry Rank

Previous Industry Rank

Website

Overall Score

Key Attributes Of Reputation

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Fastest-growing Companies

Headquarters

Sector

Current Streak

Years on List

Revenue, Net Income

Revenue past four quarters ($M)

Net Income past four quarters ($M)

Growth Rates And Ranks

Revenue 3 Yr Growth Rank

Revenue 3 Yr Annual Growth Rate

EPS 3 Yr Growth Rank

EPS 3 Yr Annual Growth Rate

Total Return 3 Yr Rank

Total Return 3 Yr Annual Rate

Beat S&P 500 3 Yr Return

Estimated P/E Ratio

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Change The World

Impact Segment

Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes medicines. Gilead’s Veklury (remdesivir) was one of the first antiviral treatments authorized for COVID-19. Gilead also pioneered groundbreaking treatments for HIV that helped transform the fatal virus into a manageable chronic condition. The company continues to expand into oncology and other chronic conditions through acquisitions, such as CymaBay, which developed a treatment for a rare liver disease.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Gilead Sciences (GILD): Company Profile, Stock Price, News, Rankings

legacy

Gilead Sciences

gilead sciences

Good afternoon, everyone, and welcome to Gilead's Fourth Quarter and Full Year twenty twenty four Earnings Conference Call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks followed by our Q and A session. Now I'll hand the call over to Jackie Ross, Senior Vice President of Treasury and Investor Relations.

Thank you, Rebecca. Just after market closed today, we issued a press release with earnings results for the fourth quarter and full year of 2024. The press release, slides and supplementary data are available on the Investors section of our website at gilead.com. The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day our Chief Commercial Officer, Joanna Mercier our Chief Medical Officer, Dietmar Berger and our Chief Financial Officer, Andrew Dickinson. After that, we'll open the call to Q and A, where the team will be joined by Cindy Peretti, the Executive Vice President of KITE.

Let me remind you that we will be making forward looking statements. Please refer to Slide two regarding the risks and uncertainties relating to forward looking statements that could cause actual results to differ materially. With that, I'll turn the call over to Dan.

Thank you, Jackie, and good afternoon, everyone. I'm pleased to share Gilead's very strong fourth quarter and full year results, which highlight growing revenues and exceptional bottom line growth. Starting with our full year performance, total product sales, excluding Viclury, increased 8% year over year to 26,800,000,000 and fourth quarter twenty twenty four total product sales excluding VICTORI increased 13% year over year to $7,200,000,000 Full year HIV sales grew 8% in 2024 to $19,600,000,000 significantly ahead of our expectation to grow HIV five percent in 2024. Full year sales for Biktarvy, the standard of care for HIV treatment grew 13%. In recent years, our HIV business has established a track record of consistently strong growth with 5% growth in 2022, '6 percent in 2023 and now 8% in 2024.

This is driven by the strength of our innovation and by the consistently strong execution of our team. In 2025, while volume and demand growth will continue, we can expect to see a temporary masking of the trend with the anticipated impact of Medicare Part D reform on revenue growth. This will effectively reset the base from which our HIV business will continue to grow from 2025. We fully expect to see our leadership in HIV continue and extend beyond the 2030s based on our long acting portfolio of which Lenacapavir is the foundation. In December, we filed for approval of Lenacapavir for twice yearly HIV prevention in The U.

S, where it has breakthrough therapy designation and we continue to make progress on our global filings. At the January, we filed for approval with the European Medicines Agency and our submission will be assessed under an accelerated review timeline. Given the unprecedented efficacy in the Phase three PROPUS one and PROPUS two trials and the significant potential that exists in HIV prevention, we are looking forward to delivering on this global opportunity in 2025 and beyond. As we shared at our HIV Analyst Day in December, we have a broad and unmatched clinical program for both HIV treatment and prevention that builds on what we currently offer with Biktarvy and Descovy. We expect to deliver up to seven potential new HIV treatment options and two prevention options before the end of two thousand and thirty three, including new daily, weekly and monthly orals, as well as quarterly and twice yearly injectables.

We look forward to sharing a number of HIV clinical updates this year, including updates from ARTISTRY-one in people with HIV on complex regimens and the Phase two portion of our WONDERS-one trial evaluating a potential once weekly HIV treatment option. Moving to inflammation, the fourth quarter of twenty twenty four was the first full quarter since commercial launch for Libelzi in The United States and we are extremely pleased with the results. The strong sales of approximately $30,000,000 for the quarter underscore the important differentiation that Libelzi brings to people with primary biliary cholangitis And we expect a European Commission decision later this month following the CHMP recommendation for LibDELSI in December. Our liver portfolio, which amounts to a $3,000,000,000 business today is a steady contributor for Gilead and we look forward to seeing it evolve with the new impetus of Lidelfy. We also continue to make progress across our early and promising inflammation pipeline.

This includes the recent addition of our STAT6 program from LEO Pharma and the advancement of our Bisestronic CAR T targeting CD19 and CD20 for autoimmune diseases. In oncology, we continue to make progress on expanding the reach of our cell therapies to the many additional patients who could benefit from a one time therapy in these challenging hematological malignancies. And at the same time, our collaboration with Arcelyx on InedoCell continues to yield promising results. Data from the registrational Phase II IMAGINE one trial were shared at the ASH meeting in December, where a needle cell demonstrated its potential to be a best in class BCMA CAR T therapy. We continue to target commercial launch in 2026 and have separately dosed our first patient in the Phase three IMAGINE three trial in the second to fourth line setting.

TRODELV, meanwhile, remains the only approved TROOP-two ADC to demonstrate overall survival benefit in pretreated HR positive HER2 negative metastatic breast cancer and in second line metastatic triple negative breast cancer. Additionally, TRODELVY has six ongoing Phase III trials with updates from the ASCENT three and ASCENT four trials in first line metastatic triple negative breast cancer expected this year. We also anticipate initiating another Phase three trial for TRIDELVY in extensive stage small cell lung cancer patients later this year. Our many near term opportunities across HIV, oncology and inflammation will help to drive the next wave of growth for Gilead. We have no major loss of exclusivity until late two thousand and thirty three and we have significant potential across the entire portfolio.

With that in mind, I'm delighted to introduce our new Chief Medical Officer, Dietmar Berger, who joined us in early January. Dietmar's exceptional leadership in global drug development, his track record in delivering transformational therapies and the breadth and depth of his experience make him an ideal leader for taking us through the next chapter for Gilead, and I know you will all enjoy getting to know him in the months ahead. I would also like to thank Merdad Parsi for his contributions to Gilead over the last five years and wish him the very best for his retirement. Among his many achievements, Merdad developed a world class team that has helped to build the most robust and diversified pipeline in Gilead's history, now with 54 ongoing clinical programs, up from just 32 clinical programs in 2019. With that, I'll hand it over to Joanna.

Thanks, Dan, and good afternoon, everyone. 2024 was another exceptional year of commercial execution for Gilead, marking the third consecutive year of high single digit percentage growth in our base business with sales up 8% year over year. Gilead's commercial success underscores the dedication of so many teams across the company and I'd like to recognize them all for contributing to another outstanding quarter and closing out a very successful year. Beginning on Slide seven with our fourth quarter results, total product sales excluding VICTORY were $7,200,000,000 an increase of 13 year over year driven by higher HIV product sales as well as growth in our oncology and liver disease portfolios. Including Veklury, total product sales grew 7% year over year reflecting the impact of lower COVID related hospitalizations on Viclury sales.

Turning to the full year on Slide eight. Total product sales excluding Viclury were $26,800,000,000 well above the high end of our 5% to 6% growth guidance range, reflecting strong performance in each of our core therapeutic areas. Including Veklury, total product sales were $28,600,000,000 a 6% growth rate compared to 2023. Moving to Slide nine. Our HIV business once again delivered very strong results for the fourth quarter with sales of $5,500,000,000 up 16% year over year primarily driven by demand as well as higher average realized price and favorable inventory dynamics.

Sequentially, HIV sales were up 7% reflecting typical seasonal inventory dynamics and higher demand partially offset by lower average realized price. In treatment, Biktarvy continues to go from strength to strength with 21% year over year sales growth. Biktarvy now commands over 50% share in The U. S. Market and maintains its position as the regimen of choice across other major G9 markets.

Descovy also delivered 21% year over year growth and maintained over 40% U. S. Market share in PrEP despite the availability of other regimens including generics. As a reminder, PrEP accounts for the majority of DyscoV revenues. We're pleased to see payers continue to recognize the benefits of PrEP as barriers to Descovy coverage are removed with over eighty five percent of lives now covered without the need for step edit or prior authorization.

On Slide 10, full year sales of $19,600,000,000 were up 8% year over year with the majority of the growth driven by higher demand as well as higher average realized price. More broadly, the HIV treatment market grew around three percent in 2024, consistent with our expectations of 2% to 3% market growth annually. In prevention, market growth accelerated and increased over 16% year over year in the fourth quarter, highlighting growing demand for HIV prevention options, which is particularly exciting to see ahead of our potential launch of lenacapavir for prevention in the summer. Preparation activities for The U. S.

Launch are well underway and we have also recently submitted marketing authorization applications to the European Medicines Agency for lenacapavir for PrEP across the EU. We can't wait to make this unique prevention option available as we look to redefine the PrEP market in the years ahead. On Slide 11, we highlight the impact of the 2025 transition to the new Medicare Part D model. As a reminder, the changes include first, the requirement that manufacturers provide discounts towards the cost of drugs for Medicare patients during the initial coverage and catastrophic phases and second, the introduction of manufacturer discounts for people who qualify for the Low Income Subsidy Program or LIF. This population is disproportionately impacted by HIV, hence this impact on our business due to the larger cost sharing obligations.

As these changes are implemented, our 2025 revenue will be impacted by approximately $1,100,000,000 of which almost $900,000,000 is in HIV. As a result and consistent with prior updates, we expect HIV revenue to be roughly flat in 2025, masking the robust demand led volume growth that we've seen consistently over the last several years in HIV and expect to continue through 2025 and into 2026 and beyond. Excluding this Medicare transition and FX headwinds, our expected HIV revenue growth in 2025 would have been at least five percent, reflecting our continued expectations for strong demand led volume growth, but offset in part by less favorable pricing assumptions due to channel mix. With regards to the first quarter of twenty twenty five specifically, we'll remind you to expect the normal HIV seasonal inventory drawdown as well as the impact of the reset of patient co pays and deductibles on average realized price and market growth. Combined with the projected IRA impact, we expect HIV revenue to decline in the mid teen percentage range quarter over quarter compared to the very strong revenue delivered in the fourth quarter.

Overall, performance of both Biktarvy and Descovy for both the quarter and full year highlight Gilead's unparalleled position in the HIV market, both in terms of the clinical profile of our therapies as well as our best in class HIV commercialization team. Moving to liver disease on Slide 12. Fourth quarter sales of $719,000,000 were up 4% year over year, reflecting our strong launch of Zildelvy in PBC and increased demand for HBV and HDD products, partially offset by lower HCD sales due to fewer patient starts. Sequentially, sales were down 2%, primarily driven by lower HCD sales due to lower average realized price and the timing of purchases, partially offset by higher sales in PBC and HBD. Full year sales of $3,000,000,000 were up 9% year over year, primarily driven by higher demand across our liver disease portfolio.

Viral hepatitis remains an important steady contributor to Gilead's revenue with our products maintaining leading share across major markets. I'm also pleased to provide an update on the early launch progress of LibDelzi on Slide 13, which received accelerated approval in The U. S. In August for the treatment of PVC. In its first full quarter of commercial availability, LibDelphi sales were $30,000,000 with demand outpacing our expectations and strong early brand share.

As the only approved therapy with statistically significant improvements in both ALP and pruritus as well as a demonstrated safety profile, we are excited to see how this positive launch momentum evolves in 2025. Outside of The U. S, last month, the MHRA in The UK approved Libelci for the treatment of PBC, including pruritus. Libelzi also received a positive CHMP opinion in December and we expect a final decision from the European Commission later this month. We're excited for these positive steps in Libelzi's development to bring this important treatment to patients globally.

Moving to Slide 14, VICLARY's fourth quarter sales of $337,000,000 were down 53% year over year and 51% sequentially, primarily due to lower rates of COVID-nineteen hospitalizations and typical of the quarterly variability we've seen with COVID-nineteen. Full year sales were $1,800,000,000 down 18% from 2023 and in line with our expectations. Moving to Oncology on Slide 15. Full year sales of $3,300,000,000 increased 12% year over year, reflecting our growing presence in this area of high unmet need and we're proud to have treated over 80,000 patients to date across TRUDELLBI and our cell therapies. On Slide sixteen, fourth quarter TRUDELLBI sales of $355,000,000 increased 19% year over year and 7% sequentially with full year sales increasing 24% year over year to $1,300,000,000 Year over year growth for both periods reflected higher demand in all regions highlighting the important role of TRUDELLVI in metastatic breast cancers, including in second line metastatic triple negative breast cancer where it's a standard of care.

In particular, Tradelvy continues to maintain market leadership in the metastatic triple negative breast cancer setting across both The U. S. And Europe and is approved in 55 markets. Combined with ongoing adoption in the pretreated HR positive HER2 negative metastatic breast cancer setting, we are pleased to see continued growing demand for TREDALVI. Moving to cell therapy on Slide 17 and on behalf of Cindy and the KITE team, full year sales of $2,000,000,000 and over 7,000 patients treated in 2024 demonstrate KITE's continued leadership in CAR T.

As expected, the fourth quarter cell therapy sales of $488,000,000 were flat on a sequential basis and up 5% year over year, reflecting the continued challenging competitive dynamics in The U. S. And in Europe. These headwinds include a number of new cell therapy launches across indications both in The U. S.

And outside The U. S. In addition to a slower than targeted uptake of cell therapy as a class. We expect continued competitive headwinds in 2025. We are making progress on our goal to make cell therapies available to large integrated community oncology practices in The U.

S. This involves addressing some of the hurdles for these networks to begin CAR T treatments, including that CAR T sites often need to be accredited by the foundation for the accreditation of cellular therapy or FACT, often enabling wider commercial reimbursement. We are working with industry groups and other manufacturers to address barriers through policy reform and exploring accreditation with groups like FACT. We look forward to sharing our progress with you in future quarters. Wrapping up 2024, I'm proud of the positive impact of Gilead's compelling portfolio of medicines on millions of people around the world.

As we look to 2025, the commercialization teams are invigorated to extend the reach of our potentially transformative medicines to even more patients and we remain focused on launch activities, including for the potential launch of LENACAPFIR for PrEP this summer. And with that, I'll hand the call over to Dietmar.

Thank you, Johanna, and good afternoon, everyone. I'm now in my sixth week as Gilead's Chief Medical Officer, and I have been impressed with the talent we have across therapeutic areas here at Gilead and the depth of innovation across our 54 clinical programs. I'm deeply committed to working alongside my colleagues to continue executing on these potentially life changing medicines. Let me start on Slide 19 by recognizing our research and development teams for their incredible work on lenacapavir, a first in class capsid inhibitor that was recently recognized by CYENS as twenty twenty four's breakthrough of the year. To put this in context, CYENS's prior HIV breakthroughs have included the discovery of HEART in 1996 and later the discovery of HIV treatment as prevention in 2011.

This achievement highlights the transformative potential of Lenacapavir and Gilead's commitment to help end the HIV epidemic for everyone everywhere. Lenacapavir for prevention was granted the FDA's breakthrough therapy designation in October, and we subsequently completed our new drug application on December 19, suggesting a possible regulatory decision in the summer. As part of our commitment to global health equity, we have filed with the EMA and are taking part in the EU Medicines for All initiative. This collaboration combines EMA's scientific review capabilities and local expertise from regulatory agencies in low- and lower middle income countries to bring medicines critical to public health to communities around the world. This process could accelerate the review process for lenacapavir in up to 138 countries worldwide.

The marketing authorization and EUM for all applications with the EMA will undergo parallel assessments under an accelerated review time line, and we anticipate a European Commission regulatory decision in the second half of this year. Lenacapavir's unique profile could similarly transform HIV treatment. On Slide 20, I highlight that we are developing seven potential new treatments using lenacapavir or lenacapavir prodrug based combinations for new daily, weekly, monthly, quarterly and twice yearly treatment options. In 2025, we expect to share an update from the Phase II WONDERS one trial evaluating the combination of GS GS1720 and GS4182 as a once weekly treatment regimen for virologically suppressed people with HIV and an update from our Phase III ARTISTRY one trial evaluating once daily bictegravir in combination with lenacapavir for virologically suppressed treatment experienced people with HIV. This medicine could serve as the first single tablet regimen for the six percent to eight percent of people with HIV on complex regimens or in other words, for people whose HIV cannot be adequately suppressed on single tablet regimens available today.

Moving to liver disease on Slide 21. The MHRA recently granted LibDelzi marketing authorization in The UK as a treatment for primary biliary cholangitis or PBC, including related pruritus. In December, we received a positive CHMP opinion for seladelpar, and we're excited to potentially bring the first and only PBC treatment shown to significantly reduce alkaline phosphatase or ALP and PBC related itch to the rest of Europe. With that said, seladelpar's clinical development is far from complete. We continue to make progress on the confirmatory Phase IIIbfour AFFIRM trial designed to support a full FDA approval.

Further, many PBC patients on ursodeoxycholic acid have ALP improvement, but do not normalize ALP, which is increasingly appreciated as a treatment goal. Patients with a persistent elevation of ALP but whose ALP levels are not above the threshold of 1.67 times the upper limit of normal have historically not been studied in clinical trials of new second line agents. We are enrolling these patients into our Phase III IDEAL trial with the hopes of demonstrating seladelpar's capacity to normalize biochemical markers of disease activity in this previously understudied patient population with incomplete control of ALP levels. Moving to oncology on Slide 22. We remain focused on clinical execution of our eight ongoing Phase III programs for TRUDEBI and dominoimab across five tumor types.

This year, we anticipate providing updates from the Phase III AASENT-three trial evaluating TRUDELLVI in first line metastatic triple negative breast cancer patients who are not candidates for anti PD-one therapy in the first half of twenty twenty five and from the Phase III AASENT-four trial evaluating TRODELV in combination with Merix pembrolizumab in first line PD L1 positive metastatic triple negative breast cancer patients in the second half of twenty twenty five. These trials could provide TRODELVY the opportunity to advance into the first line setting for metastatic triple negative breast cancer as early as 2026. Additionally, we have the Phase III ASCENT seven trial in chemotherapy naive, hormone receptor positive, HER2 negative metastatic breast cancer that completed enrollment in August of last year. In lung cancer, TRUDElvi continues to be evaluated in combination with pembro in first line PD L1 high metastatic non small cell lung cancer in the Phase III EVOKE-three study. Further, FDA has granted Frodeleby breakthrough therapy designation for extensive stage small cell lung cancer patients whose disease progressed on or after platinum based chemotherapy.

Unfortunately, most small cell lung cancer cases are diagnosed in extensive stage given the aggressive nature of the disease, and median overall survival typically is between eight and twelve months. In the small cell lung cancer cohort of the Phase II TROPICS three trial shared at World Lung last year, SODELVI demonstrated a promising thirteen point six month median overall survival. We plan to initiate the Phase III EVOKE SCLC trial in the first half of twenty twenty five. Moving to Slide 23 and on behalf of Cindy and the KITE team, we shared several exciting updates during the ASH Congress in December. In particular, we presented preliminary results from the registration of Phase II IMAGINE one trial evaluating a needle cell in fourth line or later relapsed or refractory multiple myeloma, which we believe demonstrated competitive efficacy and safety data.

Notably, in eighty six efficacy evaluable patients with a median follow-up of nine point five months, AnitoCell demonstrated an overall response rate of ninety seven percent with complete response of sixty two percent, and we expect that the responses will likely deepen over time. Minimal residual disease negativity was achieved in ninety three percent of evaluable patients. AneloCell's safety profile was generally manageable. And as of the ASH presentation, no delayed neurotoxicities have been observed across the more than one hundred and fifty patients dosed in AnitoCell trials, including no parkinsonism, no cranial nerve palsies and no Guillain Barre syndrome. We remain confident in the potential for AnidoCell to deliver a best in class profile, supported by the efficacy and safety data seen to date as well as KITE's globally leading manufacturing capabilities and continue to target 2026 for a commercial launch.

We expect to provide further data from IMAGINE one during the course of 2025. As we announced in December, the Phase III IMAGINE three trial in second to fourth line relapsed or refractory multiple myeloma has dosed its first patients, and we look forward to providing an update on ANITO cells progress in due course. Additionally, we shared updates on Yescarta and TECARDUS, which included follow-up from the ZUMA5 trial evaluating Yescarta in relapsed or refractory non Hodgkin's lymphoma, demonstrating a sixty nine percent overall survival rate at five years of follow-up. Yescarta and TECARDIS continue to demonstrate durable responses and long term overall survival that support their curative potential. We are also pleased to announce that KITE has now filed an IND application with FDA to evaluate KITE three sixty three in autoimmune conditions.

As a reminder, KITE three sixty three is a by Sistronic CAR T product that targets both CD19 and CD20, and each CAR has its own distinct co stimulatory domain. We believe cell therapy has great potential in meeting the substantial unmet needs of this large patient population, and we are excited to begin our clinical work. We will share more information when available. Joining Gilead, I look forward to working with Flavius Martin, our Executive Vice President of Research, on some of the most exciting science in the biopharma industry. On Slide 24, you can see some of the early stage targets Gilead is working on amongst an extensive pipeline of over 100 innovative pre IND and clinical stage programs.

Finally, on Slide 25, we have several interesting milestones this year, including regulatory decisions on lenacapavir and seladelpar, Phase III updates for our bictegravir and lenacapavir combination as well as TRODELBI and Phase II updates for Anida Cell in fourth line plus multiple myeloma and for our weekly oral HIV treatment. We are also initiating new Phase III trials, including in extensive stage small cell lung cancer and across our long acting HIV prevention programs that should bring forth new exciting updates in the years to come. And now I'll hand the call over to Andy.

Thank you, Dietmar, and good afternoon, everyone. Starting on Slide '27, we closed the year with total product sales of $28,600,000,000 up 6% from 2023 and well above our $27,800,000,000 to $28,100,000,000 guidance range due to stronger than expected contributions from HIV. For the full year, total product sales excluding Vectlury grew more than $2,000,000,000 or 8% from 2023, exceeding our 5% to 6% guidance range and driven by growth in HIV, oncology and liver. HIV increased 8% or $1,400,000,000 to $19,600,000,000 driven by Biktarvy, which grew 13% from 2023. Oncology increased 12% to $3,300,000,000 primarily driven by growth in TRUDELLVI and with a more modest growth contribution from cell therapy.

And liver increased 9% to $3,000,000,000 with growth across our portfolio of liver treatments. Full year VACLURE revenue of $1,800,000,000 was right in line with our expectations and declined 18% from 2023, consistent with pandemic and hospitalization trends. Moving to Slide '28. Our full year non GAAP results highlight consistent expense discipline in 2024. R and D of $5,700,000,000 was flat with 2023.

IPR and D of 4,700,000,000 included $3,900,000,000 associated with the SimaBay acquisition in the first quarter in addition to our normal course IPR and D expenses. And SG and A of $5,900,000,000 was down 3% from 2023. Overall, 2024 operating income was $8,500,000,000 ahead of our guidance range of $8,000,000,000 to $8,300,000,000 Note full year operating margin of 30% reflects the first quarter twenty twenty four acquisition of SimaBay. Excluding this transaction, our operating margin would have been 43 for the full year. Similarly, non GAAP EPS of $4.62 reflects the $3.14 per share impact of this transaction.

Excluding this, our non GAAP EPS would have been $7.75 up 15% from the $6.72 reported in 2023. Moving to our fourth quarter results starting on Slide 29. Total product sales excluding Vectlury were $7,200,000,000 up 13% from the same quarter in 2023. Including Vectlury, total product sales of 7,500,000,000 were up 7% from 2023 with higher base business growth partially offset by a decline in Vectlury sales. On Slide 30, you can see that on a non GAAP basis, product gross margin was approximately 87% compared to 86% in the same period in 2023.

R and D expenses were $1,600,000,000 up from $1,500,000,000 in the same period in 2023, reflecting incremental investments and clinical activities across our portfolio. Acquired IPR and D was negative $11,000,000 reflecting expenses related to the Terray and Tubulus collaborations offset by a favorable adjustment related to the CIMIBE acquisition. Note that the acquisition of certain rights from LEO's STAT VI program will be reflected in our first quarter twenty twenty five results. SG and A was $1,900,000,000 up 16% from the same period in the prior year, partially driven by a litigation accrual for a potential settlement with the U. S.

Attorney's Office for the Southern District of New York relating to our promotional speaker programs for HIV medicines. Additionally, there was higher sales and marketing spending, including launch preparation activities for lenacapavir for HIV prevention as well as for Libelzi for PBC. Operating margin was 41%, up from 39% in the fourth quarter of twenty twenty three and the effective tax rate in the fourth quarter was 19.2% compared to 17.1% in the same period in 2023, primarily due to prior year settlements with tax authorities. Overall, our non GAAP diluted earnings per share was $1.9 in the fourth quarter compared to $1.72 in the fourth quarter of twenty twenty three. Moving to Slide 31 and before I get into guidance, I want to remind you of certain factors that are impacting our revenue expectations for 2025 and masking the underlying strength of our business.

As previously discussed, Medicare Part D reform is expected to impact our revenue by approximately $1,100,000,000 including $900,000,000 in HIV. For this year only, this transition masked the robust demand led volume growth that we have seen over the last several years and that we expect to continue through 2025 and into 2026 and beyond. Across our entire business, this represents about a 4% impact on revenue growth in 2025. Second, you can see that our Vectlory expectations are about $400,000,000 lower in 2025 versus 2024, representing an additional growth headwind of roughly 1%. And finally, our guidance reflects a $250,000,000 headwind from FX given the U.

S. Dollar has strengthened against major foreign currencies, offsetting another approximately 1% of expected growth. You can see that excluding the IRA, FX and Vectlury headwinds, our guidance today would have been for total product revenue growth of approximately 5% to 6%. On Slide 32, you can see our guidance for 2025, which assumes a generally stable macro environment, including FX at current rates. For the full year 2025, we expect total product sales of approximately $28,200,000,000 to $28,600,000,000 We expect total product sales excluding Veklury of approximately $26,800,000,000 to $27,200,000,000 We expect Veklury sales of approximately $1,400,000,000 although as always there is greater variability in this estimate.

Similar to last year, we do not expect to update our Vectlury guidance until our third quarter earnings call, absent a very clear trend in COVID-nineteen infections. Moving to the rest of the P and L and on a non GAAP basis, we expect product gross margin to range between 8586%. We expect R and D to be roughly flat from 2024, highlighting that we believe we now have the appropriate scale of investment to support our diverse pipeline. We expect acquired IP R and D to be approximately $400,000,000 and includes roughly $250,000,000 associated with the acquisition of LEO Pharma STAT6 program announced in January. The remaining $150,000,000 we are guiding to today reflects known commitments and expected milestone payments.

Consistent with our approach over the last two years, we will highlight incremental acquired IPR and D expenses as we announce new transactions and update our guidance each quarter. And finally, we expect SG and A to decline by a high single digit percentage compared to 2024. Excluding the litigation accrual in 2024, our SG and A would decline a mid single digit percentage in 2025, reflecting our ongoing commitment to operating expense discipline. As a result, we expect our operating income for 2025 to be between $12,700,000,000 and $13,200,000,000 We expect our effective tax rate to be approximately 19%. And finally, we expect our non GAAP diluted EPS to be between $7.7 and $8.1 for the full year and GAAP diluted EPS to be between $5.95 and $6.35 As a reminder, for the first quarter of twenty twenty five, we expect HIV revenue to decline in the mid teen percentage range compared to the very strong revenue delivered in the fourth quarter due to both normal inventory drawdown in the first quarter coupled with the IRA headwind.

Moving to capital allocation on Slide 33, our priorities have not changed. In 2024, we returned $5,100,000,000 to shareholders. This included $3,900,000,000 in dividend payments and $1,200,000,000 in share repurchases. For 2025, we announced today a 2.6% increase in our quarterly cash dividend to $0.79 per share, and we remain committed to growing our dividend over time. You can also expect to see continued investments in our business both internally and externally through select partnerships and business development transactions.

Finally, we will continue to utilize share repurchases to offset equity dilution as well as additional repurchases on an opportunistic basis. With that, I'll invite Rebecca to begin the Q and A.

Thank you, Andy. At this time, we'll invite your questions. We ask that you be courteous and please limit yourself to one question so that we can get to as many analysts as possible during today's call. Our first question comes from Geoff Meacham at Citigroup. Geoff, go ahead.

Great. Thank you. Afternoon, guys. In HIV, I know you guys are looking at lin and PrEP to be a big growth driver over time, but I wanted to ask about the HIV treatment setting. I guess the question is, do you guys view all the different LEN treatment options that you detail on Slide 20 as eventually replacing Biktarvy?

I wasn't sure how you're thinking about what the best approach is for lifecycle management and even prior to the Biktarvy LOE. Thank you.

Jeff, let me just welcome everybody to the call again. I'll just turn it over to Joanna and I'll just ask the speakers as they respond to questions to just introduce themselves. So Joanna, over to you.

Geoff. Thanks for the question. Listen, absolutely, our strategy is definitely an opportunity to just make sure that we meet the patient needs. And that is really now that Biktarvy has set the standard of care for HIV treatment, we believe that the only thing that's left is looking at long acting orals or long acting injectables. And so we will have an opportunity as we think about the Big Glenn daily oral to a weekly actually two weekly orals and then potentially even a little bit longer term with the six month layers or whatnot, have an opportunity to look at the marketplace and it automatically will erode some of the Biktarvy shares, right?

As you think about a share of over 50 as the market leader, there will be opportunities for us to think about as a total Gilead portfolio well prior to the LOE in late two thousand and thirty three of Biktarvy. So there's a lot of optionality here as we think about what's to come. And there will be opportunities as long as it, for us, it hits the standard of care that Biktarvy has set plus brings optionality for patients with the long acting administration.

Our next question comes from Terence Flynn at Morgan Stanley. Terence, go ahead. Your line is open.

Great. Thanks so much for taking the question. Just a two part on guidance. Just wanted to understand what is included, if anything at all, for Lend for prep in the '25 revenue guide? And then, it's great to see the margin expansion coming through again in '25 here.

And based on your comments, Andy, I'm assuming we should assume that this is kind of the steady state level as we think about the forward into 'twenty six as well, but just wanted to check there. But thanks so much.

Yes. Terence, it's Andy. Thanks for the question. Look, in terms of lenacapavir, we're assuming a launch mid year. As we've said, Joanna has said consistently that we'll we expect to have meaningful access and access will build over time.

Obviously, at launch, you're working on adding to your access as quickly as possible. So I think after six months, we expect to have 75% access in The U. S. And well north of that after nine months and then a year. But we are assuming a launch in the middle of the year.

So that but beyond that, I don't think there's much that we can say at this point in time. In terms of the expenses, you're absolutely right. I mean, we saw very strong expense control in 2024. Despite I will also highlight when you look at 2024 there were a couple of unexpected items at the beginning of the year that actually increased our expenses. One of them is the litigation reserve that I highlighted in our prepared remarks that you saw in the fourth quarter.

The second, of course, are all the operating expenses for that related to the Libelzi acquisition that we absorbed throughout the year. So even with that, you saw incredibly strong expense control throughout the year. And you see in our guidance that we expect to carry that forward in 2025. So the last thing I'll say to your question is that we have said we are targeting holding our expenses relatively flat for the foreseeable future and letting the leverage in our model drop to the bottom line and that has not changed. We of course will provide more specific guidance on what that means for 2026 and 2027 when we get there.

But it's a great start to the year. I look forward to updating you as we progress.

Our next question comes from Tim Anderson at Bank of America. Tim, go ahead. Your line is open.

Thank you for the question. Lynn at Capivir and Prep, so as we approach launch, concerns sometimes start to build whether consensus could be too high relative to what the product could actually deliver in their initial few quarters after launch. So in as much as you've looked at consensus, any comment on what you see or perhaps you can just refresh us on the ramp dynamics we need to consider. I know you just talked about access as one of those. And will this be a fast, a slow, a medium paced launch?

Any benchmarks for similar launches you'd like to point us to?

Sure. It's Joanna. I'll take that question, Tim. So as you know, we're very excited about the potential launch of Lenacapavir this summer. It's we don't give product specific guidance, so I can't help you there.

What I can tell you is in line with what Andy was saying about access, we do think access will ramp up, but it doesn't mean there won't be access until six months, right? Access will play out over the next few months, of a launch. We're assuming about 75% or so access by six months, maybe about 90% by twelve months. We also think the administration, because this is an injectable, it's going to have to go through specialty pharmacy or a buy and bill model. So that might just, you know, take a little bit of time in the first early months to make sure we ramp up for that administration.

But we feel incredibly confident that lena Kapavir is going to have an impact in our communities, in 2025 and obviously even more meaningful in 'twenty six and beyond.

Our next question comes from Umer Raffat at Epicor ISI. Go ahead. Your line is open.

Hi, guys. Thanks for taking my question and huge congratulations to Dietmar, on joining. I wanted to focus very briefly on some of the AnitoCell data you guys have shared. Obviously, a ton of very good color on the non ICANS side. I thought I would focus for a quick second on ICANS more specifically, the nine cases of ICANS that happened in the IMAGINE ONE trial.

And my question is, how many of those nine cases had of ICANS had tremors, bradykinesia or any other motor dysfunction? And did any of the cases happen more than a couple of weeks after the administration? Thank you.

Thanks, Umer. This is Cindy Peretti, for the question. I'm not going to be able to answer probably at the level of detail you're looking for for each one of those ICANS, and I know we can come back with you. But we did not see, we did not see cases of tremors in those patients. And I can come back on the other two.

Our next question comes from Michael Yee at Jefferies.

Great. Thanks. Looking ahead to the approval of LEN for PrEP, can you just comment about your recent interactions with the FDA and the perspective of the FDA and HHS with the incoming administration with The U. S. And that there should be no issues with a fast approval?

And simultaneously in Europe, that has never really gained significant revenue. So you highlight that as an approval and do you somehow see that reimbursement is going to be different there?

I'll just start and hand it over to either Joanna or Dietmar. Thanks, Michael, for the question. Everything is on track for the lenticaprevir for PrEP interactions with the agency and HHS. So, we're continuing all preparation accordingly and getting ready for the approval this summer, as we discussed before, on Europe. I don't know.

Yes, it's more of a commercial question. I would just add, we also got breakthrough designation from the FDA in The U. S. For lenticapacare. And so we're excited about the potential for this launch this summer.

And everything's on track for that and our plans are obviously all the teams are working through to make sure we are ready, for that launch. In Europe, two things. One is the approval for Europe, the potential approval, I should say, for Europe is one that we find exciting and one that we realize that prevention in Europe is really specific to certain markets more so than others. We are obviously going to do that in a tiered approach and make sure that we're really targeting both all key stakeholders. That includes government, health ministers, government stakeholders, KOLs, investigators, with the purpose five trial that we have running right now in The UK and in France, and making sure that we work together really across different stakeholder groups to make sure that there's an opportunity for lena Kapavir to have access in these countries and really make a difference for those markets.

So more to come on that. We also think that the EU filing is an important one, because of EU for all. And that really is around providing access to those over 138 countries for low and lower middle income countries as well. And so that's in line with the work that we're doing to ensure access everywhere around the world. So more to come on that as we progress.

Our next question comes from Dana Graybosch at Leerink Partners. Dana, go ahead. Your line is open.

This is for Dietmar. I wonder as you've come in new to the organization, if you could give us your reflections on the competitiveness of the late stage oncology portfolio, particularly what you think about TIGIT and DAWN and Trotoby, as we come to more Phase three readouts? Thank you.

Yeah. Thanks, Dana, for the question, right? As I join Gilead, right, Gilead is in a unique situation at this point with a well diversified clinical pipeline, no major LOEs before 02/1933, really upcoming key launches and strong news flow that I'm looking forward to and an exciting research portfolio and really deep scientific expertise that I consider critical, right, in these areas, whether it's virology, whether it's a long standing history or whether it's immunology and oncology. Your specific question with regards to the later stage portfolio, look through Delphi, the key studies are set up at this point and we're looking forward to seeing the ASCEND three and ASCEND four studies in triple negative breast cancer coming up during this year basically. So that question will be answered very soon.

We also have the lung cancer studies in the first line setting, really set up at this point. And let me just remind you that FODELVEY is the only drop to ADC that has demonstrated overall survival in some of those studies, right? So I think it's a really differentiated molecule and a lot of it will uncover itself in the very near future. For TIGIT, I've always believed TIGIT is an interesting immuno oncology target. There's potential for differentiation given the fact that donganelumab has the FC silent design.

There were some encouraging early Phase II data like the ARK7, the ARK10 study, the EdgeGastric study, but those were, of course, small early data sets. So again, we're awaiting the data. There are two ongoing Phase III studies, STAR one to one and STAR two to one, which really will define our path forward there.

Our next question comes from Mohit at Wells Fargo. Mohit Bansal, your line is open.

Great. Thank you very much for taking my question and welcome, Geetmar, to Gilead. So So my question is regarding the sales growth for HIV quarter over quarter. It seems like you're calling out favorable inventory dynamic year over year as well. So just wanted to understand, did you see more than normal inventory buildup in fourth quarter?

Because you're calling out year over year as well.

Thanks, Mohit. It's Joanna. So what we did see is obviously really strong demand in both the quarter over quarter as well as the full year on year Q4 over Q4 of the prior year. We also did see seasonal inventory dynamics and we see that on a quarter on quarter basis, but also a little bit year on year. And what we have seen in 2023 is actually that inventory build across Q3 and Q4.

In 2024, we saw it heavily in Q4 instead of across two quarters. And so that's probably the biggest difference that we've seen from a year on year basis. But really, the number one driver across the board for HIV, first and foremost, has been that demand, that has come through, namely on Biktarvy but also Descovy.

Our next question comes from Brian Abrahams at RBC Capital Markets. Brian, go ahead. Your line is open.

Hey, guys. Congratulations on the quarter. Thanks for taking my question. Maybe shifting gears to Lidelsi, curious if you could elaborate a little bit more on what you're observing in terms of just use pattern prescriber base, the types of patients where this early uptake is coming from and maybe how we should at least qualitatively be thinking about the trajectory this year just given the high demand you're seeing off the bat? Thanks.

Sure. Thanks for the question, Brian. It's Joanna. Yes, so with Libtowsy, we're really excited about how not only are we seeing the progression, but it's definitely exceeding our internal expectations. We've heard some really positive feedback on the differentiation of efficacy, but also safety, not just the ALP, but also just the overall biochemical response, the ALP normalization and of course the pruritus and the safety components to this.

We are seeing strong continuous week over week growth. And so that's creating momentum as we go into 2025. So we're very much looking forward to that. And I think it has a lot to do with the experience, the heritage that we have in liver, the credibility that we bring with key stakeholders. So very pleased about that.

The payer access we're seeing is also in line with our expectations, for rare disease. We're not seeing any major barriers to getting access for appropriate patients. To your question about what type of patients, obviously, these are second line patients in line with our indication. Generally speaking, these are second naive to second line. And what I mean by that is obviously, they're inadequate responders to UDCA and moving into the second line setting.

Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript

Company Participants